ARS Pharmaceuticals Inc
Research ARS Pharmaceuticals Inc (SPRY) on Bullrun: market cap USD 568.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSPRY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 568.78M
- Financial periodQ1 2026
- RevenueUSD 22.68M
- Net income-USD 197.98M
- Free cash flow-USD 175.32M
- Gross margin323.5%
Valuation Snapshot
latest market cap is USD 568.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 84.28M | -USD 171.30M | -USD 171.21M | 75.8% | -1.74 | USD 41.32M | USD 96.37M | USD 114.26M |
| FY2024 | USD 89.15M | USD 8.00M | USD 12.99M | 98.9% | 0.08 | USD 50.82M | USD 0 | USD 256.80M |
| FY2023 | USD 30.00K | -USD 54.37M | -USD 59.44M | 100.0% | -0.57 | USD 70.97M | USD 274.00K | USD 230.76M |
| FY2022 | USD 1.32M | -USD 34.68M | -USD 40.28M | n/a | -0.87 | USD 210.52M | USD 7.25M | USD 272.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 568.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.16B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.03B | 131.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 526.07M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 799.86M | n/a | n/a | n/a |
About ARS Pharmaceuticals Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ARS Pharmaceuticals Inc's market cap?
ARS Pharmaceuticals Inc's market capitalization is USD 568.78M.
What does ARS Pharmaceuticals Inc do?
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.